Sarepta Therapeutics Inc [SRPT] stock prices are up 1.45% to $22.32 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SRPT shares have gain 5.58% over the last week, with a monthly amount glided 18.03%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sarepta Therapeutics Inc [NASDAQ: SRPT] stock has seen the most recent analyst activity on December 09, 2025, when Wedbush initiated its Outperform rating and assigned the stock a price target of $32. Previously, Mizuho upgraded its rating to Outperform on November 05, 2025, and kept the price target unchanged to $26. On September 22, 2025, upgrade upgraded it’s rating to Outperform but maintained its price target of $50 on the stock. Oppenheimer upgraded its rating to an Outperform but stick to its price target of $37 on July 29, 2025. JP Morgan upgraded its rating to a Neutral but $24 remained the price target by the analyst firm on July 29, 2025. Barclays upgraded its rating to Equal Weight for this stock on July 29, 2025, but kept the price target unchanged to $22. In a note dated July 29, 2025, H.C. Wainwright reiterated an Sell rating on this stock but restated the target price of $5.
The stock price of Sarepta Therapeutics Inc [SRPT] has been fluctuating between $10.41 and $129.84 over the past year. Currently, Wall Street analysts expect the stock to reach $22.89 within the next 12 months. Sarepta Therapeutics Inc [NASDAQ: SRPT] shares were valued at $22.32 at the most recent close of the market. An investor can expect a potential return of 2.55% based on the average SRPT price forecast.
Analyzing the SRPT fundamentals
The Sarepta Therapeutics Inc [NASDAQ:SRPT] reported sales of 2.41B for trailing twelve months, representing a drop of -14.52%. Gross Profit Margin for this corporation currently stands at 0.75% with Operating Profit Margin at -0.05%, Pretax Profit Margin comes in at -0.1%, and Net Profit Margin reading is -0.11%. To continue investigating profitability, this company’s Return on Assets is posted at -0.08, Equity is -0.2 and Total Capital is -0.05. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.95.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.94 points at the first support level, and at 21.56 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.58, and for the 2nd resistance point, it is at 22.84.
Ratios To Look Out For
It’s worth pointing out that Sarepta Therapeutics Inc [NASDAQ:SRPT]’s Current Ratio is 2.95. In addition, the Quick Ratio stands at 1.78 and the Cash Ratio stands at 0.67. Considering the valuation of this stock, the price to sales ratio is 0.97, the price to book ratio is 1.77.
Transactions by insiders
Recent insider trading involved Estepan Ian Michael, Chief Operating Officer, that happened on Dec 16 ’25 when 13187.0 shares were sold. Officer, IAN M ESTEPAN completed a deal on Dec 16 ’25 to buy 13187.0 shares. Meanwhile, Shareholder Sarepta Therapeutics, Inc. bought 9.27 million shares on Aug 13 ’25.
